Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -143.44% is 148% below its 5-year average of -57.74%, near the low end of its 5-year range (-143.44%–-34.22%).
110.43% below its 12-month average of -68.17%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -31.07%.
RETURN ON ASSETS (ROA)
-143.44%
RETURN ON ASSETS (ROA) AVG TTM
-68.17%
RETURN ON ASSETS (ROA) AVG 3Y
-65.00%
RETURN ON ASSETS (ROA) AVG 5Y
-57.74%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-110.43%
CURRENT VS 3Y AVG
-120.66%
CURRENT VS 5Y AVG
-148.42%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-344.91%
vs the sector median at left
Passage Bio, Inc.
Market Cap
$13.08M
Return on Assets (ROA)
-143.44%
TTM Avg
-68.17%
3Y Avg
-65.00%
5Y Avg
-57.74%
Market Cap
$13.20M
Return on Assets (ROA)
-32.53%
TTM Avg
-31.07%
3Y Avg
-30.77%
5Y Avg
-29.89%
Market Cap
$13.33M
Return on Assets (ROA)
-85.85%
TTM Avg
-102.78%
3Y Avg
-95.22%
5Y Avg
-76.09%
Market Cap
$12.77M
Return on Assets (ROA)
-47.98%
TTM Avg
-31.15%
3Y Avg
-42.27%
5Y Avg
-34.21%
Market Cap
$12.54M
Return on Assets (ROA)
-60.93%
TTM Avg
-160.25%
3Y Avg
-205.49%
5Y Avg
-152.09%
Market Cap
$12.51M
Return on Assets (ROA)
-49.12%
TTM Avg
-29.80%
3Y Avg
-67.98%
5Y Avg
-117.36%
Market Cap
$13.69M
Return on Assets (ROA)
-27.12%
TTM Avg
-32.94%
3Y Avg
-35.27%
5Y Avg
-29.16%
Market Cap
$12.43M
Return on Assets (ROA)
-420.14%
TTM Avg
-127.99%
3Y Avg
-97.65%
5Y Avg
-85.48%
Market Cap
$12.31M
Return on Assets (ROA)
-216.84%
TTM Avg
-118.20%
3Y Avg
-6127.40%
5Y Avg
-4092.56%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Passage Bio, Inc. (PASG) | $13.08M | -143.44% | -68.17% | -65.00% | -57.74% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.20M | -32.53% | -31.07% | -30.77% | -29.89% |
| IN8bio, Inc. (INAB)vs › | $13.33M | -85.85% | -102.78% | -95.22% | -76.09% |
| Cytosorbents Corporation (CTSO)vs › | $12.77M | -47.98% | -31.15% | -42.27% | -34.21% |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.54M | -60.93% | -160.25% | -205.49% | -152.09% |
| Dare Bioscience, Inc. (DARE)vs › | $12.51M | -49.12% | -29.80% | -67.98% | -117.36% |
| Optimi Health Corp. (OPTH)vs › | $13.69M | -27.12% | -32.94% | -35.27% | -29.16% |
| Tempest Therapeutics, Inc. (TPST)vs › | $12.43M | -420.14% | -127.99% | -97.65% | -85.48% |
| Lantern Pharma Inc. (LTRN)vs › | $12.31M | -216.84% | -118.20% | -6127.40% | -4092.56% |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $12.39M | -77.94% | -178.68% | -1009.31% | -2782.57% |
ROA
-143.4%
ROE
-810.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -73.09% |
| 2024-12-31 | -63.24% |
| 2023-12-31 | -67.80% |
| 2022-12-31 | -55.89% |
| 2021-12-31 | -52.21% |
| 2020-12-31 | -34.22% |
| 2019-12-31 | -25.55% |
| 2018-12-31 | -38.16% |
